Drug Profile
Subutinib
Alternative Names: Subutinib maleateLatest Information Update: 18 Apr 2016
Price :
$50
*
At a glance
- Originator Jiangsu Chia-Tai Tianqing Pharmaceutical
- Developer Chia Tai Tianqing Pharmaceutical Group
- Class Antineoplastics; Maleates
- Mechanism of Action Enzyme inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 07 Mar 2013 Phase-I clinical trials in Solid tumours in China (PO)
- 30 Sep 2012 Preclinical trials in Solid tumours in China (PO)